Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ5YMH)

Drug Name

(11E)-OCTADEC-11-ENOIC ACID Drug Info

Synonyms

cis-vaccenic acid; (Z)-octadec-11-enoic acid; cis-11-Octadecenoic acid; 506-17-2; 11Z-Octadecenoic acid; (11E)-octadec-11-enoic acid; Asclepic acid; (Z)-11-Octadecenoic acid; 11-Octadecenoic acid, (Z)-; UNII-400K7322UW; CHEBI:50464; 400K7322UW; cis-octadec-11-enoic acid; VCA; trans-11-Octadecensaeure; 11-cis-Octadecenoic acid; C18:1n-7; cis-11-Vaccenic acid; AC1NR0QT; 11(Z)-Octadecenoic acid; cis-D11-Octadecenoic acid; SCHEMBL97463; (11Z)octadec-11-enoic acid; (11Z)-octadec-11-enoic acid; CHEMBL1236642; UWHZIFQPPBDJPM-FPLPWBNLSA-N

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5282761
ChEBI ID: CHEBI:50464
CAS Number: CAS 506-17-2
TTD Drug ID: DMZ5YMH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Peroxisome proliferator-activated receptor delta (PPARD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GFT-505	DM7ZOAE	Non-alcoholic steatohepatitis	DB92.1	Phase 3	[2]
MBX-8025	DMNTCV4	Obesity	5B81	Phase 2/3	[3]
T3D-959	DMR3245	Alzheimer disease	8A20	Phase 2	[4]
T3D-959	DMR3245	Alzheimer disease	8A20	Phase 2	[5]
KD3010	DMNFDYE	Metabolic disorder	5C50-5D2Z	Phase 1	[6]
SAR351034	DM15PG9	Dyslipidemia	5C80-5C81	Phase 1	[7]
CER-002	DMLBKZV	Dyslipidemia	5C80-5C81	Phase 1	[8]
PMID25416646-Compound-Figure5-C	DM17FKL	N. A.	N. A.	Patented	[9]
GW-501516	DMPL2KM	Type-1 diabetes	5A10	Discontinued in Phase 4	[10]
Sodelglitazar	DMJ816F	Hyperlipidaemia	5C80	Discontinued in Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor delta (PPARD)	TT2JWF6	PPARD_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
2	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
3	ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
4	Phrma report (2013 Alzheimers disease)
5	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
6	Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
7	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
8	Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
9	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
10	Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
11	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.